Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 30 of 283 for:    Tumor infiltrating lymphocytes

Study of People With Metastatic Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating Lymphocytes in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03538613
Recruitment Status : Withdrawn (NCI not moving forward with study execution.)
First Posted : May 28, 2018
Last Update Posted : October 4, 2018
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )

Brief Summary:

Background:

The gene CISH can weaken immune cells called lymphocytes. It is found in all cells of the body but it most negatively impacts lymphocytes. This study may help people with certain cancers.Lymphocyte cells will be taken from their tumors, the CISH gene will be removed from those cells, then the cells will be returned to the person. Researchers hope this process will help the cells work better and fight the tumors.

Objective:

To see if cells with the CISH gene removed are safe and shrink metastatic gastrointestinal epithelial tumors.

Eligibility:

People 18 70 years old with metastatic gastrointestinal epithelial cancer

Design:

Participants will be screened with physical exam, scans, and heart, lung, blood, and urine tests.

Participants will have cells collected in another protocol. They must tell their doctor of any antibiotic allergy.

The cells will be changed in a lab. Participants will stop therapy 4 6 weeks before getting the cells back.

Participants will have leukapheresis. Blood is sent by a needle in one arm into a machine that takes out the white blood cells. The blood is returned through a needle in the other arm.

Participants will have an IV catheter inserted in their upper chest to receive medicines and the cells.

Participants will stay in the hospital and:

  • Have chemotherapy for 1 week
  • Get the cells for about a half hour to a little over an hour
  • Get a cell growth medicine about every 8 hours for up to 12 doses
  • Get medicines to boost blood cells and fight side effects
  • Recover for 1 3 weeks.

Participants will have 2 follow-up visits within 12 weeks of treatment, then a couple visits each year. They will repeat screening tests.


Condition or disease Intervention/treatment Phase
Gastrointestinal Epithelial Cancer Gastrointestinal Neoplasm Cancer of Gastrointestinal Tract Cancer, Gastrointestinal Drug: Cyclophosphamide Drug: Fludarabine Drug: Aldesleukin Biological: CISH inactivated TIL Phase 1 Phase 2

Detailed Description:

BACKGROUND:

  • CISH (Cytokine-induced SH2 protein) is an important negative regulator of T-cell signaling. The knockout or knockdown of CISH in mouse anti-tumor lymphocytes results in a profound increase in the ability of these lymphocytes to mediate tumor regression following administration to tumor bearing mice. These cells have a profound advantage in inducing anti-tumor responses compared to the wild-type anti-tumor lymphocytes.
  • We have developed and optimized a CRISPR/Cas9 based strategy for highly efficient gene disruption in primary human T-cells without sacrificing cell viability or function.
  • Thus, in this protocol we propose to disrupt the gene encoding CISH in lymphocytes from patients with metastatic cancers that are selected for anti-tumor activity.

OBJECTIVES:

Primary objectives:

  • To determine the safety of the administration of mutation reactive autologous lymphocytes with knockout of the CISH gene in patients with refractory metastatic gastrointestinal epithelial cancer.
  • To determine the response rate of the administration of mutation reactive TIL with knockout of CISH gene in patients with refractory metastatic gastrointestinal epithelial cancers.

ELIGIBILITY:

  • Age greater than or equal to 18 years and less than or equal to 70 years
  • Evaluable metastatic gastrointestinal epithelial cancer refractory to standard chemotherapy
  • Metastatic cancer lesions suitable for surgical resection for the preparation of TIL
  • No allergies or hypersensitivity to high-dose aldesleukin administration
  • No concurrent major medical illnesses or any form of immunodeficiency

DESIGN:

  • Patients with evaluable metastatic gastrointestinal epithelial cancer will undergo a resection of tumor under the NCI Surgery Branch companion protocol 03-C-0277.
  • The study will begin in a standard phase I dose-escalation. After the MTD cell dose has been determined, patients will be enrolled into the Phase II portion of the trial at the MTD established during the Phase I portion of the study.
  • Patients will receive a non-myeloablative, lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of the CISH knockout lymphocytes plus IV aldesleukin.
  • In the Phase II portion, the study will be conducted using a phase II optimal design where initially 21 evaluable patients will be enrolled. If 0 or 1 of the first 21 patients experiences a clinical response, then no further patients will be enrolled but if 2 or more of the first 21

evaluable patients enrolled have a clinical response, then accrual will continue until a total of 41 evaluable patients have been enrolled.

  • The objective will be to determine if the treatment regimen is able to be associated with a clinical response rate that can rule out 5% (p0=0.05) in favor of a modest 20% PR + CR rate (p1=0.20).
  • Up to 60 patients may be enrolled over 5 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Trial in Patients With Metastatic Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating Lymphocytes in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System
Actual Study Start Date : May 17, 2018
Actual Primary Completion Date : September 10, 2018
Actual Study Completion Date : September 10, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 1/Phase I Arm
Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine +escalating doses of CISH inactivated TIL + high-dosealdesleukin
Drug: Cyclophosphamide
Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg /day X 2 days over 1 hr.

Drug: Fludarabine
Days -7 to -3: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days.

Drug: Aldesleukin
Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes every 8 hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).

Biological: CISH inactivated TIL
Day 0: Each bag of autologous CISH inactivated TIL for infusion will be administered intravenously (IV) on the Patient Care Unit over 10-20 minutes.

Experimental: 2/Phase II Arm
Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine +MTD of CISH inactivated TIL
Drug: Cyclophosphamide
Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg /day X 2 days over 1 hr.

Drug: Fludarabine
Days -7 to -3: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days.

Drug: Aldesleukin
Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes every 8 hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).

Biological: CISH inactivated TIL
Day 0: Each bag of autologous CISH inactivated TIL for infusion will be administered intravenously (IV) on the Patient Care Unit over 10-20 minutes.




Primary Outcome Measures :
  1. Maximum tolerated cell dose (MTD) [ Time Frame: Before progression to next higher dose level ]
    Highest dose at which less than or equal to 1 of 6 patients experienced a DLT or the highest dose level studied if DLTs are not observed at any of the dose levels

  2. Response rate [ Time Frame: 6 and 12 weeks after cell infusion, then every 3 months x3, then every 6 months x 5 years, then per PI discretion ]
    Percentage of patients who have a clinical response to treatment (objective tumor regression)

  3. Frequency and severity of treatment-related adverse events [ Time Frame: 5 years after cell infusion ]
    Aggregate of all adverse events, as well as their frequency and severity


Secondary Outcome Measures :
  1. Survival and persistence of CISH inactivated TIL [ Time Frame: 3, 6, and 12 months post cell administration, and then yearly for 15 years ]
    Assess for any long-term effects resulting from the cell administration. Samples will be batched and analyzed to check for the presence of the transferred cells.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  • INCLUSION CRITERIA:

Inclusion Criteria to Enroll and Prepare Cells for Shipping to UMN for Processing:

  1. Measurable metastatic gastrointestinal epithelial cancer with at least one lesion that is resectable for TIL generation, plus one other lesion that can be measured.
  2. Confirmation of diagnosis of metastatic gastrointestinal epithelial cancer by the NCI Laboratory of Pathology.
  3. Patients with 3 or fewer brain metastases that are less than 1 cm in diameter and asymptomatic are eligible. Lesions that have been treated with stereotactic radiosurgery must be clinically stable for 1 month after treatment for the patient to be eligible. Patients with surgically resected brain metastases are eligible.
  4. Progressive disease following at least one first line standard therapy.
  5. Age greater than or equal to 18 years and less than or equal to 70 years.
  6. Clinical performance status of ECOG 0 or 1.
  7. Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatment.
  8. Serology:

    • Seronegative for HIV antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive can have decreased immune-competence and thus may be less responsive to the experimental treatment and more susceptible to its toxicities.)
    • Seronegative for hepatitis B antigen, and seronegative for hepatitis C antibody. If hepatitis C antibody test is positive, then patient must be tested for the presence of antigen by RT-PCR and be HCV RNA negative.
    • Blood sample submitted for additional testing per national blood banking standards (e.g., anti-HTLV-I/II, anti-T. cruzi, West Nile Virus NAT, anti-CMV, RPR), for purposes of proper handling and storage
  9. Willing to sign a durable power of attorney.
  10. Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document
  11. Subjects must be co-enrolled on protocol 03-C-0277 (Cell Harvest and Preparation for Surgery Branch Adoptive Cell Therapy Protocols).

Inclusion Criteria for Eligibility to Receive Treatment

  1. Women of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the treatment on the fetus.
  2. Hematology:

    • Absolute neutrophil count greater than 1000/mm^3 without the support of filgrastim
    • WBC greater than or equal to 3000/mm^3
    • Platelet count greater than or equal to 100,000/mm^3
    • Hemoglobin greater than 8.0 g/dl. Subjects may be transfused to reach this cut-off.
  3. Chemistry:

    • Serum ALT/AST less than 5.0 x ULN
    • Serum creatinine less than or equal to 1.6 mg/dl
    • Total bilirubin less than or equal to 2.0 mg/dl, except in patients with Gilbert s Syndrome, who must have a total bilirubin less than or equal to 3.0 mg/dl.
  4. More than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients toxicities must have recovered to grade 1 or less (except for toxicities such as alopecia or vitiligo).

Note: Patients may have undergone minor surgical procedures within the past 3 weeks, as long as all toxicities have recovered to grade 1 or less.

EXCLUSION CRITERIA:

Exclusion Criteria for Eligibility to Receive Treatment

  1. Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant.
  2. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease).
  3. Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immunecompetence may be less responsive to the experimental treatment and more susceptible to its toxicities).
  4. Active systemic infections requiring anti-infective treatment, coagulation disorders or any other active major medical illnesses.
  5. Concurrent systemic steroid therapy.
  6. History of severe immediate hypersensitivity reaction to cyclophosphamide, fludarabine, or aldesleukin.
  7. History of coronary revascularization or ischemic symptoms.
  8. Documented LVEF less than or equal to 45% tested in patients:

    • Age greater than or equal to 65 years
    • With clinically significant atrial and/or ventricular arrhythmias, including but not limited to: atrial fibrillation, ventricular tachycardia, second- or third-degree heart block, or have a history of ischemic heart disease and/or chest pain.
  9. Clinically significant patient history which in the judgment of the PI would compromise

    the patients ability to tolerate high-dose aldesleukin.

  10. Documented FEV1 less than or equal to 50% predicted tested in patients with:

    • A prolonged history of cigarette smoking (approximately 20 packs/year within the past 2 years).
    • Symptoms of respiratory dysfunction
  11. Patients who are receiving any other investigational agents.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03538613


Sponsors and Collaborators
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Steven A Rosenberg, M.D. National Cancer Institute (NCI)

Publications:
Layout table for additonal information
Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT03538613     History of Changes
Other Study ID Numbers: 180103
18-C-0103
First Posted: May 28, 2018    Key Record Dates
Last Update Posted: October 4, 2018
Last Verified: September 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) ):
Adoptive Cell Therapy
Immunotherapy
Gene Therapy

Additional relevant MeSH terms:
Layout table for MeSH terms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Cyclophosphamide
Fludarabine phosphate
Fludarabine
Aldesleukin
Vidarabine
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antimetabolites, Antineoplastic
Antimetabolites
Antiviral Agents
Anti-Infective Agents
Anti-HIV Agents
Anti-Retroviral Agents